Exagen draws $5.3M for rheumatology Dx development

Exagen Diagnostics pulled in $5.3 million in new financing from a number of investors that it plans to use for both market growth and product development. Tullis Health Investors led the round, which also included Sun Mountain Capital, Cottonwood Technology Fund, Mesa Verde Venture Partners and Epic Ventures. Exagen already has three rheumatology-related diagnostic products and is developing a number of new ones to address rheumatology-related disorders. Release

Suggested Articles

The former CEO of the molecular testing company Foundation Medicine, Troy Cox, has been named chairman of the Swiss big data firm Sophia Genetics.

Researchers at MIT used a machine-learning algorithm to uncover the potent antibiotic properties hiding within an old small-molecule candidate.

The randomized, blinded study showed statistically significant improvements in assessments of inattention and brain activity.